6 June 2016 - The EMA has published an EPAR for MedImmune's pandemic H5N1 influenza vaccine.

The European Commission approved MedImmune's vaccine on 20 May 2016 for the prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age. Pandemic influenza vaccine H5N1 MedImmune should be used in accordance with official guidance.

The vaccine, which is given as a nasal spray, will be subjected to additional monitoring by the EMA.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003963/human_med_001984.jsp&mid=WC0b01ac058001d124